Drugs / huCART19-IL18-eDHFR cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07343934 | May 2026 → Nov 2027 expected | B-cell neoplasm | University of Pennsylvania | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | huCART19-IL18-eDHFR cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07343934 ↗ |
| Modality | Cell therapy | “Genetically modified autologous T cells engineered by co-transduction with two lentiviral vectors” NCT07343934 ↗ |
| Route | Intravenous | “IV administration of a single flat dose of 7x10\[6\] huCART19-IL18-eDHFR cells.” NCT07343934 ↗ |
| Target | CD19 | “one vector expressing a chimeric antigen receptor (CAR) targeting the CD19 antigen” NCT07343934 ↗ |